ALP AI
Redefining Biologics
Through Immunogenicity Intelligence
Redesigning antibodies with AI to reduce immunogenicity and anti-drug antibody (ADA) responses
ALP AI In A Nutshell
We eliminate immunogenic liabilities early so the right drugs can win.
Problem
Anti-Drug Antibody (ADA) effects are hard-to-mitigate risk of late-stage biologic failure, costing pharma billions
Solution
Unique tonsil organoid-trained immunogenicity platform predicts and mitigates ADA risks early in hit generation
Business Model
ADA prevention platform for antibody drug pipelines; future expansion into proprietary biobetter assets
Current IP
Licensed core tech + Proprietary innovations, Patent pipeline, Established lab + beta model
First ADA-optimized mAbs generated
Book a Demo
Antibody translation model
Our demo model can take any heavy variable domain of an antibody as input and uses a protein language model to generate a humanized version.
The output score is the probability, according to our model, that the sequence is human.
Do you have a sequence in mind that needs to be translated? Book a demo with us.
- No commitments
- 30 min. call
- See our model in action
Founding Team
CEO
Dr. Christian Vahlensiek
Christian leads ALP AI with a clear vision to transform biologics by preventing immunogenicity. With a PhD in bioinformatics and experience advising global pharma on R&D AI at McKinsey, he brings together scientific depth and real-world AI product expertise.
CSO
Dr. Lucas Schaus
Lucas is the scientific lead behind ALP AI’s ADA prevention platform. During his PhD under Prof. Steve Mayo, he developed the core algorithm and wetlab proof of concept, combining deep immunology insight with data-driven rigor.
CTO
Anatol Ehrlich
Anatol leads ALP AI’s technical development, combining AI expertise with a systems mindset. With dual Master’s degrees and a PhD in computer science, he’s focused on building scalable infrastructure to power biological insight.
CBO
Punit Mehra
Punit leads business development and partnerships at ALP AI, translating deep-tech into scalable value. With a background in Chemical and Bioengineering from ETH Zurich and startup experience, he drives strategic engagement with biopharma.